MART-1 (27-35) (human) TFA
Based on 1 Customer Validation
MART-1 (27-35) (human) TFA is the amino acid fragment spanning positions 27 to 35 of the MART-1 protein, and it represents an immunogenic epitope recognizable by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TILs). MART-1 (27-35) (human) TFA can be used in studies related to melanoma.
For research use only. We do not sell to patients.
- Purity: 98.12%
- Formula: C37H67N9O11·xC2HF3O2
- Molecular Weight:813.98 (free base)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
MART-1 (27-35) (human) (0.1-10 μM; 2 h at room temperature then 24 h at 4 °C) TFA binds to purified human HLA-A2 molecules, and this binding is detectable via fluorescent signals[1].
MART-1 (27-35) (human) (10 μM; overnight at 4 °C for initial complex formation) TFA forms an HLA-A2 complex, which almost completely dissociates within 24 h at 37 °C[1].
MART-1 (27-35) (human) (1 μg/mL; 1 h incubation with T2 cells, 4 h cytolytic assay) TFA is specifically recognized by human MART-1 (27-35)-specific, HLA-A2-restricted TIL clones LT8, LT11 and LT12, and induces T2 target cells to release high levels of 51Cr[1].
MART-1 (27-35) (human) (0.0001-10 μg/mL; 1 h) TFA sensitizes HLA-A*0201+ T2 cells to lysis by CLW anti-MART-1 (27-35) CD8+ cytotoxic T lymphocytes (CTLs) in a dose-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HLA-A*0201+ T2 target cells, anti-MART-1(27-35) CD8+ CTL line (CLW)
-
Concentration:10-10-10-5 g/mL
-
Incubation Time:1 h (incubation with target cells)
-
Result:Induced dose-dependent specific 51Cr release from T2 cells.
Reached significant lysis at concentrations of 10-8 g/mL and above.
Achieved maximum specific 51Cr release of 100% at the highest tested concentration (10-5 g/mL).
Chemical Information
-
Appearance Solid
-
Molecular Weight 813.98 (free base)
-
Formula C37H67N9O11·xC2HF3O2
-
Color White to off-white
-
Sequence
Ala-Ala-Gly-Ile-Gly-Ile-Leu-Thr-Val
-
Sequence Shortening
AAGIGILTV
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 7.14 mg/mL (ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Guichard G, et al. Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes. J Med Chem. 2000;43(20):3803-3808. [Content Brief]
[2]. Loftus DJ, et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med. 1996;184(2):647-657. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MART-1 (27-35) (human) TFA Related Classifications
HY-106187B Related Classifications
Powered by Bioz